Open AccessScreening for Autoantibodies in Type 1 Diabetes: A Call to Action
Author(s) -
Anne L. Peters
Publication year - 2021
Publication title -
the journal of family practice
Language(s) - English
Resource type - Journals
eISSN - 1533-7294
DOI - 10.12788/jfp.0223
Subject(s) - medicine , autoantibody , glycemic , diabetic ketoacidosis , type 1 diabetes , incidence (geometry) , ketoacidosis , diabetes mellitus , disease , type 2 diabetes , immunology , pediatrics , intensive care medicine , endocrinology , antibody , physics , optics
KEY TAKEAWAYS• Type 1 diabetes (T1D) is an autoimmune disease that progresses through 3 distinct stages.• T1D can be diagnosed at any age, with a peak incidence at 10-14 years of age.• The incidence of T1D in the United States is rising.• Screening for T1D autoantibodies has positive clinical consequences, including reduction of diabetic ketoacidosis events, improved glycemic control, and positive impact on short- and long-term complications.• Primary care clinicians can play a critical role in promoting islet autoantibodyscreening.